Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo.
Article Details
- CitationCopy to clipboard
Lu J, Chong CR, Hu X, Liu JO
Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo.
J Med Chem. 2006 Sep 21;49(19):5645-8.
- PubMed ID
- 16970390 [ View in PubMed]
- Abstract
The fumagillin family of natural products inhibits angiogenesis through the irreversible inhibition of the type 2 methionine aminopeptidase (MetAP2). Herein is reported a novel fumagillin analogue named fumarranol. It is shown that, like fumagillin, fumarranol selectively inhibits MetAP2 and endothelial cell proliferation. It is also active in a mouse model of angiogenesis in vivo. Unlike TNP-470, fumarranol does not covalently bind to MetAP2. Fumarranol may serve as a lead for a new class of angiogenesis inhibitors.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) TNP-470 Methionine aminopeptidase 2 IC 50 (nM) 1 N/A N/A Details